|12.75||-0.2200||-1.70%||Vol 156.24K||1Y Perf -31.12%|
|Aug 16th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||40.75||Analyst Rating||Moderate Buy 1.80|
|Potential %||219.61||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||26.88||Earnings Rating||—|
|Market Cap||479.03M||Earnings Date||12th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.85|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||189.74K|
|Avg. Monthly Volume||250.53K|
|Avg. Quarterly Volume||365.93K|
Akero Therapeutics Inc. (NASDAQ: AKRO) stock closed at 12.75 per share at the end of the most recent trading day (a -1.7% change compared to the prior day closing price) with a volume of 156.24K shares and market capitalization of 479.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Akero Therapeutics Inc. CEO is Andrew Cheng.
The one-year performance of Akero Therapeutics Inc. stock is -31.12%, while year-to-date (YTD) performance is -39.72%. AKRO stock has a five-year performance of %. Its 52-week range is between 7.52 and 26.98, which gives AKRO stock a 52-week price range ratio of 26.88%
Akero Therapeutics Inc. currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 3.37, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.01%, a ROC of -57.85% and a ROE of -59.80%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Akero Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.85 for the next earnings report. Akero Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Akero Therapeutics Inc. is Moderate Buy (1.8), with a target price of $40.75, which is +219.61% compared to the current price. The earnings rating for Akero Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akero Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akero Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.36, ATR14 : 0.96, CCI20 : 86.53, Chaikin Money Flow : -0.03, MACD : 0.70, Money Flow Index : 69.83, ROC : 26.54, RSI : 53.62, STOCH (14,3) : 72.26, STOCH RSI : 0.13, UO : 56.77, Williams %R : -27.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akero Therapeutics Inc. in the last 12-months were: Andrew Cheng (Option Excercise at a value of $51 045), Andrew Cheng (Sold 90 000 shares of value $1 894 650 ), Catriona Yale (Sold 25 000 shares of value $578 431 ), Jonathan Young (Option Excercise at a value of $17 063), Jonathan Young (Sold 37 500 shares of value $907 623 ), William R. White (Option Excercise at a value of $242 224), William R. White (Sold 34 559 shares of value $779 762 )
Fri, 22 Jul 2022 09:37 GMT Akero Therapeutics (AKRO) was Downgraded to a Hold Rating at Evercore ISI- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.